Overview

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
Phase:
Phase 2
Details
Lead Sponsor:
Sucampo AG
Sucampo Pharma Americas, LLC
Collaborators:
Sucampo AG
Sucampo Pharma Americas, LLC
Takeda
Treatments:
Lubiprostone